» Articles » PMID: 20456487

Hepcidin Treatment in Hfe-/- Mice Diminishes Plasma Iron Without Affecting Erythropoiesis

Overview
Publisher Wiley
Specialty General Medicine
Date 2010 May 12
PMID 20456487
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Iron is essential for mammalian metabolism and its cellular concentration is controlled by regulating its acquisition and storage. Haemochromatosis is a condition involving iron overload that is characterised by increased duodenal iron absorption and a progressive accumulation of iron in vital organs. Hepcidin is the main hormone that regulates iron homoestasis and it is secreted by the liver.

Materials And Methods: We have studied how extended hepcidin administration affects the iron load status, plasma and tissue iron concentration, erythropoiesis and the expression of proteins involved on iron homeostasis in haemochromatotic (Hfe(-/-)) and wild-type mice.

Results: Hepcidin reverted the high plasma iron concentrations in Hfe(-/-) mice to normal values. The high concentration of hepatic iron was not altered in the liver of these Hfe(-/-) mice. Hepcidin administration did not disturb erythropoiesis in either Hfe(-/-) or wild-type mice and likewise, hepcidin did not modify the expression of any protein analysed in the liver, duodenum or spleen of Hfe(-/-) and wild-type mice. These data confirm that hepcidin administration diminishes plasma iron concentrations.

Conclusion: Treatment with sustained doses of hepcidin diminishes plasma iron concentrations in Hfe(-/-) mice.

Citing Articles

Protein Susceptibility to Peroxidation by 4-Hydroxynonenal in Hereditary Hemochromatosis.

Sanchez-Jaut S, Perez-Benavente S, Abad P, Mendez-Cuadro D, Puyet A, Diez A Int J Mol Sci. 2023; 24(3).

PMID: 36769239 PMC: 9917916. DOI: 10.3390/ijms24032922.


A computational model to understand mouse iron physiology and disease.

Parmar J, Mendes P PLoS Comput Biol. 2019; 15(1):e1006680.

PMID: 30608934 PMC: 6334977. DOI: 10.1371/journal.pcbi.1006680.


Hepcidin Therapeutics.

Katsarou A, Pantopoulos K Pharmaceuticals (Basel). 2018; 11(4).

PMID: 30469435 PMC: 6316648. DOI: 10.3390/ph11040127.


Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Liu J, Sun B, Yin H, Liu S Medicine (Baltimore). 2016; 95(14):e3150.

PMID: 27057839 PMC: 4998755. DOI: 10.1097/MD.0000000000003150.


Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis.

Chen B, Li G, Shen Y, Huang X, Xu Y Exp Ther Med. 2015; 10(1):7-11.

PMID: 26170904 PMC: 4486897. DOI: 10.3892/etm.2015.2484.